| (i) A patient with breast cancer, lymphangiosis carcinomatosa and shortness of breath declined |
| chemotherapy and received mistletoe infusions (Iscador) every 3 weeks. Each time, this substantially |
| improved her breathing for a period of 2 weeks. She lived five years after diagnosis of |
| lymphangiosis and 10 years since diagnosis of breast cancer. (General practitioner) |
| (ii) One patient with a huge inoperable colorectal carcinoma, metastases in the liver and lymph |
| nodes and an additional renal cell cancer was first treated with intratumoral and subcutaneous |
| applications. The tumor became harder and encapsulated. Due to gastrointestinal bleeding, the |
| tumor, which had a weight of 5-6 kg, was removed (R0). After recovery from postoperative septic |
| complications, the patient received MT subcutaneously and intravenously. His condition improved |
| and stabilized. The patient returned to work despite his liver and bone metastases and lived for at |
| least 3 more years until he died of a sudden cardiac arrest. (Internist) |
| (iii) A patient over 70 years old with a partly resected metastatic sigmoid colon cancer (T4) refused |
| chemotherapy. She received infusions (Helixor, rhythmic dosages 100–500 mg) and lived well for 6 more |
| years. She later also agreed to a temporary oral capecitabine treatment. The ultrasound showed an |
| encapsulation of the tumor. After 6 years, the tumor induced heavy bleeding in the sigma and the |
| patient died. (General practitioner) |
| (iv) One patient with a large pseudomyxoma peritonei, encircling large parts of the colon, had been |
| treated with multiple operations, hyperthermia, chemotherapy and anthroposophic medicine. The |
| tumor led to a rectovaginal fistula. The patient was then treated with fever-inducing mistletoe infusions |
| (Iscador M spezial, 5 mg). A CT scan showed a slight improvement, and the fistula closed up temporarily. |
| The patient lived with her disease for 15 years and was still alive at the time of the interview. (Oncologist) |
| (v) One patient with advanced inoperable prostate cancer and bone metastases (one in the pelvis at a |
| size of 10 cm) received intravenous and partly intratumoral MT, and partly hormones and |
| chemotherapy; he survived 12 years. (Neurologist, intensive care specialist) |
| (vi) Another patient with prostate cancer and lymph node metastases had received hormone treatment |
| (bicalutamid, goserelin), which led to a reduction in PSA levels. After about 5 months, he engaged in a |
| new partnership and gave great importance to his sexual function and thus terminated hormone |
| treatment. After some months of increasing the PSA levels, an intravenous MT (Helixor M, 10–1500 mg) |
| was started, intensifying the previous standard subcutaneous application. This led to a stabilization of |
| PSA levels for 1 year. (Oncologist) |
| (vii) A patient had a rapidly growing glioblastoma at an initial size of 15 cm. Due to the rapid growth, the |
| patient’s first surgery was followed by re-surgery after only 2 weeks, and the subsequent radiotherapy |
| terminated after 4 weeks. As this point, the tumor was already larger than its size before the first |
| surgery. Mistletoe infusions were started and the situation stabilized. The patient lived for 1 more year. |
| (Neurologist, intensive care specialist) |
